Dateline City:
KENILWORTH, N.J.
Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76 th Scientific Sessions of the American Diabetes Association
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
today announced results from two Phase 3 studies evaluating MK-1293,
Mercks investigational, follow-on biologic* insulin glargine candidate
for the treatment of people with type 1 and type 2 diabetes.
Language:
English
Contact:
MerckMedia:Doris Li, 908-246-5701Kristen Drake, 908-334-4688orInvestor:Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more